236 related articles for article (PubMed ID: 16444796)
1. Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed.
Payne DC; Franzke LH; Stehr-Green PA; Schwartz B; McNeil MM
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):46-54. PubMed ID: 16444796
[TBL] [Abstract][Full Text] [Related]
2. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; West DJ;
Pharmacoepidemiol Drug Saf; 2002; 11(3):189-202. PubMed ID: 12051118
[TBL] [Abstract][Full Text] [Related]
3. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003.
Payne DC; Rose CE; Kerrison J; Aranas A; Duderstadt S; McNeil MM
Arch Neurol; 2006 Jun; 63(6):871-5. PubMed ID: 16769869
[TBL] [Abstract][Full Text] [Related]
4. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; Ward BJ; West DJ
Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):825-40. PubMed ID: 15386719
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database.
Geier MR; Geier DA
Hepatogastroenterology; 2004; 51(57):762-7. PubMed ID: 15143911
[TBL] [Abstract][Full Text] [Related]
6. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
[TBL] [Abstract][Full Text] [Related]
7. A comparative assessment of immunization records in the Defense Medical Surveillance System and the Vaccine Adverse Event Reporting System.
McNeil MM; Ma G; Aranas A; Payne DC; Rose CE
Vaccine; 2007 Apr; 25(17):3428-36. PubMed ID: 17258846
[TBL] [Abstract][Full Text] [Related]
8. Surveillance for adverse events associated with anthrax vaccination--U.S. Department of Defense, 1998-2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Apr; 49(16):341-5. PubMed ID: 10817479
[TBL] [Abstract][Full Text] [Related]
9. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
[TBL] [Abstract][Full Text] [Related]
10. Assessment of anthrax vaccination data in the Defense Medical Surveillance System, 1998-2004.
Payne DC; Rose CE; Aranas A; Zhang Y; Tolentino H; Weston E; McNeil MM; Ruscio B
Pharmacoepidemiol Drug Saf; 2007 Jun; 16(6):605-11. PubMed ID: 17437247
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program.
Fowler GL; Baggs JM; Weintraub ES; Martin SW; McNeil MM; Gust DA
Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):880-8. PubMed ID: 16924600
[TBL] [Abstract][Full Text] [Related]
12. Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature.
McNeil MM; Chiang IS; Wheeling JT; Zhang Y
Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):259-74. PubMed ID: 17245803
[TBL] [Abstract][Full Text] [Related]
13. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
14. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.
Tierney BC; Martin SW; Franzke LH; Marano N; Reissman DB; Louchart RD; Goff JA; Rosenstein NE; Sever JL; McNeil MM;
Clin Infect Dis; 2003 Oct; 37(7):905-11. PubMed ID: 13130401
[TBL] [Abstract][Full Text] [Related]
15. Anthrax vaccination in the Millennium Cohort: validation and measures of health.
Smith B; Leard CA; Smith TC; Reed RJ; Ryan MA;
Am J Prev Med; 2007 Apr; 32(4):347-53. PubMed ID: 17383567
[TBL] [Abstract][Full Text] [Related]
16. Quality assessment of nonanthrax vaccination data in the Defense Medical Surveillance System (DMSS), 1998-2004.
Davila JC; Payne DC; Zhang Y; Rose CE; Aranas A; Hill AN; Ruscio B; McNeil MM
Vaccine; 2008 Mar; 26(12):1577-84. PubMed ID: 18295379
[TBL] [Abstract][Full Text] [Related]
17. European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome.
Fritsch P
Eur J Dermatol; 2008; 18(2):216-7. PubMed ID: 18424404
[No Abstract] [Full Text] [Related]
18. Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the U.S. Military: A Case-Control Study.
Bardenheier BH; Duffy J; Duderstadt SK; Higgs JB; Keith MP; Papadopoulos PJ; Gilliland WR; McNeil MM
Mil Med; 2016 Oct; 181(10):1348-1356. PubMed ID: 27753574
[TBL] [Abstract][Full Text] [Related]
19. Results of a safety and immunogenicity study of an early-stage investigational rPA102 vaccine as compared to the FDA licensed anthrax vaccine (anthrax vaccine adsorbed (AVA. BioThrax)).
Hannesschlager JR
Vaccine; 2007 Apr; 25(17):3247. PubMed ID: 17234308
[No Abstract] [Full Text] [Related]
20. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(45):1024-6. PubMed ID: 12458919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
